BioMérieux Shares Hit Seven-Year Low After Disappointing Quarter

Triggered by First Quarter Revenue Announcement

The publication of the first quarter 2026 revenue triggered the downward trend. bioMérieux recorded revenues of 984 million euros for the period, a 3.9% organic decline, hampered by a lackluster respiratory season and an uncertain macroeconomic environment. Concurrently, the group revised its outlook for the full year downwards, a signal that intensified selling pressure. Over the week, the stock has fallen by 21.57%, with a three-month loss reaching 31.1%. Over the year, the market capitalization has shrunk by more than 37%. The next major financial event is scheduled for July 28, the date of the 2026 half-year results publication, which will assess the extent of the deterioration and the group's ability to correct its course.

In the European healthcare sector, the trend is also downward this Friday: Sanofi is down 0.77% and UCB falls by 2.23% during the session. The CAC 40 drops 1.05% in mid-morning, while the SBF 120 loses 1.00%, in a generally unfavorable market context.

Technical Analysis Shows Marked Deterioration

From a technical standpoint, bioMérieux's chart shows significant deterioration. The price, at 71.45 euros, is well below the lower Bollinger band set at 81.78 euros, placing the stock in a pronounced oversold territory. This assessment is corroborated by an RSI that has dropped to 18, a rarely seen level indicating an extreme imbalance between buyers and sellers in the short term. An RSI below 30 is generally considered an oversold threshold; at 18, the indicator is well below this mark.

The stock is also significantly distanced from its reference moving averages: the MM50 is at 92.77 euros and the MM200 at 107.68 euros, representing respective gaps of more than 20 euros and more than 36 euros from the current price. This distance illustrates the severity of the recent drop. The previous support threshold identified at 73.25 euros was breached this morning, with the price breaking this level downward to register its seven-year low. The next technical resistance is now at 95.05 euros, a target more than 33% above the current price.